Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.

ABSTRACT:

Objectives

Although brentuximab vedotin (BV) has changed the management of patients with relapsed or refractory Hodgkin lymphoma (RRHL), little information is available on routine clinical practice. We identified treatment patterns and costs of care among RRHL patients in the United States (US) treated with BV.

Methods

A retrospective observational study of adults initiating BV for RRHL from 2011-2015, with ≥6 months of data prior to and following BV initiation, was conducted. Treatments were classified based on dispensations and chemotherapy administration. Median total and monthly costs were estimated based on all-cause healthcare resource use in 2015 US dollars (USD).

Results

The cohort comprised 289 patients (59% male; mean age at diagnosis, 42 years) with a mean

SUBMITTER: Szabo SM 

PROVIDER: S-EPMC5633181 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature